DUBLIN--(BUSINESS WIRE)--
ICON
plc, (NASDAQ: ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today reported that Moody's Investors Service has
assigned ICON a corporate credit rating of Baa3 and Standard & Poor's,
has assigned ICON a corporate credit rating of BBB-, both with a stable
outlook.
Commenting on the investment grade ratings, Brendan Brennan, ICON's
Chief Financial Officer said: "We are delighted with the investment
grade credit ratings assigned by both rating agencies, which reflects
the quality of ICON's business, the strong track record of growth and
profitability, high levels of cash generation, and very strong balance
sheet."
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 89 locations in 38 countries and
has approximately 11,900 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON/ICLR-F
View source version on businesswire.com: http://www.businesswire.com/news/home/20160105005748/en/
ICON plc
Investor Relations, 1-888-381-7923
or
Brendan
Brennan, + 353 -1-291-2000
Chief Financial Officer
or
Simon
Holmes, + 353 -1-291-2000
EVP Investor Relations and Corporate
Development
Source: ICON plc
News Provided by Acquire Media
